What clinical data supported the approval of ICOTYDE?

The approval of ICOTYDE was supported by data from four Phase 3 clinical studies, involving around 2,500 patients. These studies demonstrated that ICOTYDE achieved high levels of skin clearance with a safety profile that was favorable when compared to existing injectable therapies.

How is Johnson & Johnson involved in the commercialization of ICOTYDE?

Under a long-standing development and license agreement, Johnson & Johnson (NYSE:JNJ) will lead the global commercialization of ICOTYDE. The drug will be integrated into Johnson & Johnson’s immunology portfolio, enabling it to benefit from the company’s established market presence and infrastructure in the immunology space.

What financial milestone did Protagonist Therapeutics reach with this approval?

The FDA approval of ICOTYDE triggers a $50 million milestone payment from Johnson & Johnson to Protagonist Therapeutics. This payment reflects the achievement of a major regulatory milestone in the drug’s development.

What further financial incentives is Protagonist eligible for?

Beyond the initial $50 million milestone, Protagonist Therapeutics is eligible for up to $580 million in additional development and sales-based milestones. This provides the company with a significant financial upside tied to the continued success of ICOTYDE in the market.

Image for illustrative purposes only. Not a real photo.

Protagonist Therapeutics shares surge as FDA approves J&J-partnered psoriasis drug

Written by Mahathir BayenaPublished Mar 18, 2026, 12:00 AM

Protagonist Therapeutics (NASDAQ:PTGX) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older weighing at least 40 kg.

The approval marks a major clinical victory for the company’s oral peptide technology and significantly strengthens its financial position.

The regulatory green light was supported by data from four comprehensive Phase 3 clinical studies involving approximately 2,500 patients.

The trials demonstrated that ICOTYDE achieved high levels of skin clearance with a safety profile that compared favorably to existing injectable therapies.

Under a long-standing development and license agreement, Johnson & Johnson (NYSE:JNJ) will lead the global commercialization of the drug, integrating it into its market-leading immunology portfolio.

The approval immediately triggers a $50 million milestone payment from Johnson & Johnson to Protagonist.

Beyond the initial windfall, Protagonist remains eligible for up to $580 million in additional development and sales-based milestones.

Furthermore, the company will receive tiered royalties ranging from 6% to 10% on net global sales, providing a consistent, long-term revenue stream that management expects will fund its internal pipeline of next-generation oral therapeutics.